Phaseline

Targets › EBP

EBP (3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Sep 2029.

Isomerase that catalyzes the conversion of Delta(8)-sterols to their corresponding Delta(7)-isomers a catalytic step in the postlanosterol biosynthesis of cholesterol..; FUNCTION: Component of the microsomal antiestrogen binding site (AEBS), a multiproteic complex at the ER membrane that consists of an association between EBP and 7-dehydrocholesterol reductase/DHCR7. This complex is responsible for…. (UniProt, Q15125)

Open in Phaseline: the race on EBP, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Washington University School of MedicineDSP-0390
EBP (emopamil binding protein) inhibitor; inhibits de novo cholesterol synthesis
EBPPhase 1Small-cell Lung CancerSep 2029

Conditions

Small-cell Lung Cancer (1)

Modalities

mixed (1)

Companies

Washington University School of Medicine (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.